The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors.
 
Toshio Kubo
Honoraria - Kyowa Hakko Kirin; Taiho Pharmaceutical
 
Katsuyuki Hotta
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Takashi Ninomiya
Honoraria - Boehringer Ingelheim; Chugai Pharma
 
Hironari Kato
No Relationships to Disclose
 
Shigeru Horiguchi
No Relationships to Disclose
 
Atsushi Takamoto
No Relationships to Disclose
 
Toshiyuki Kozuki
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Naoyuki Nogami
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Hiroshi Ishii
Honoraria - Astellas Pharma; Chugai Pharma; Eisai; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; Nobelpharma; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Taiho Pharmaceutical
 
Tomohiro Nishina
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Daijiro Harada
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Kyowa Hakko Kirin; Lilly Japan; Ono Pharmaceutical; Yakult Honsha
 
Shinichi Toyooka
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson; Kyorin; Medtronic; Ono Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
 
Hiroyuki Okada
No Relationships to Disclose
 
Toshiyoshi Fujiwara
No Relationships to Disclose
 
Heiichiro Udono
Research Funding - Ono Pharmaceutical (Inst)
 
Katsuyuki Kiura
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)